AI management approved for type 2 diabetes

Israel’s DreaMed (see here previously) has now received US FDA approval for use with Type 2 diabetes sufferers as well as Type 1. It will relieve the strain on endocrinologist who each have on average some 46,000 patients.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.